Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Is Proactive On Procrit Positioning Ahead Of Medicare Part B Changes

Executive Summary

Johnson & Johnson is taking steps to competitively position Procrit ahead of the changes to Medicare Part B reimbursement in 2005, Biopharmaceuticals Group Chairman Joe Scodari told investors July 13
Advertisement

Related Content

Aloxi Payment Cut By One-Third Under Medicare ASP Rule
Aloxi Payment Cut By One-Third Under Medicare ASP Rule
EPO Ceasefire? Amgen Aranesp Price To Remain Stable Unless J&J Acts First
J&J Draws Line On Procrit Price; Will Not Meet Amgen Aranesp 40% Discount
J&J Draws Line On Procrit Price; Will Not Meet Amgen Aranesp 40% Discount
Amgen Discounting Aranesp After Medicare Reimbursement Cut

Topics

Advertisement
UsernamePublicRestriction

Register

PS044356

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel